Ok TrueTrades, based on what you mentioned, I don't think INNV/Novalare (or whoever was the manufacturer, ANDA) ever received any FDA, CLR regarding Fluticare.
My opinion is that Dr.Damaj should never have mentioned a possible FDA Fluticare OTC approval date, he should have said that it could take up to 12/31/17 barring any glitches.
It appears to me that big pharma GSK/Bayer has been influential in regard to getting the FDA to drag it's feet regarding Fluticare review/approval.
Based on this, I think the FDA might take until 12/31/17 to approve/deny Fluticare and possibly all the way up until 1/31/18.
I don't think GSK/Bayer are able to instruct the FDA regarding to many nasal spray options being on the market, because that would F over part of our free market economy.
However, I do think the FDA would naturally concentrate on review fast tracked anti cancer drugs, for example, versus nasal sprays.
If and when the ANDA for Fluticare is approved, I don't think it will make any difference in INNVs share price.
In my opinion, the only thing that will effect the PPS in a positive direction is increased sales and lowered costs, equaling profitability.
